Search

Your search keyword '"Plat, Victor D."' showing total 30 results
Start Over Author "Plat, Victor D."
30 results on '"Plat, Victor D."'

2. Esophageal and gastric malignancies after bariatric surgery: a retrospective global study

Author

Gallardo, Carlos Sosa, Agustin, Cataldo, Wright, Fernando, Fuente, Ignacio, Carbajo, Miguel, Cal, Patricio, Chisholm, Jacob, Kow, Lilian, Tan, Michael H.L., Gan, Philip, Gananadha, Sivakumar, Felsenreich, Daniel M., Prager, Gerhard, Matthys, Chris, Himpens, Jacques M., Focquet, Marc A.M.R.M., Ramos, Almino, Nato, Manoel Galvano, Vidal, Thiago, Andalib, Amin, Siblini, Aya, Ferri, Lorenzo, Abdarabo, Lina, Nevo, Yehonatan, Pescarus, Radu, Yang, Wah, Hamed, Hosam, Liagre, Arnaud, Bergeat, Damien, Marie, De Montrichard, Martini, Francesco, Regis, François, Genser, Laurent, Skalli, Mehdi, Nedelcu, Marius, Smejkal, Milan, Kassir, Radwan, Nicolas, Regenet, Stier, Christine, Nedelcut, Dan-Sebastian, Christodoulidis, Grigorios, Vennapusa, Amar, Kermansaravi, Mohammad, Raziel, Asnat, Sakran, Nasser, Oldani, Alberto, Boru, Cristian Eugeniu, Mécheri, Fouzia, Ciccarese, Francesca, Cesana, Giovanni Carlo, Musella, Mario, Uccelli, Matteo, Foletto, Mirto, Auricchio, Pasquale, Olmi, Stefano, Seki, Yosuke, Kasteleijn, Anne, Van 'T Hof, Gerhard, Apers, Jan A., Hart, Judith W.H., Van De Sande, Justin S.L., Takkenberg, Marijn, Feskens, Pierre B.G.M., Snoekx, Rob, Plat, Victor D., Sandvik, Jorunn, Kalinowski, Piotr, Nabais, Celso, Al-Bahrani, Ahmed Z., Al Zoubi, Mohammad, Bettonica, Carla, Osorio, Javier, Tejedor-Tejada, Javier, Sanz, Lourdes M., Cuadrado, Marta, Moorjani, Rajesh Gianchandani, Yannick, Fringeli, Suter, Michel, Borbély, Yves, Joerg, Zehetner, Barajas-Gamboa, Juan S., Kroh, Matthew, Kisiel, Aaron P., Kamocka, Anna, Immanuel, Arul, Sgromo, Bruno, Gopinath, Bussa, Khoo, David, Mukherjee, Samrat, Pournaras, Dimitrios, Underwood, Tim, Griffiths, Ewen A., Miller, Glenn V., Jaretzke, Helen, Dmitrewski, Jan, Wadley, Martin S., Al-Housni, Ragad, Gillies, Richard S., Singhal, Rishi, Preston, Shaun R., Robinson, Steven John, Hawkins, William J., Adamo, Marco, El Kalaawy, Mohamed, Gossage, James, Crawford, Christopher B., Jaruvongvanich, Veeravich, Parmar, Chetan, Zakeri, Roxanna, Abouelazayem, Mohamed, Shin, Thomas H., Aminian, Ali, Mahmoud, Tala, Abu Dayyeh, Barham K., Wee, Melissa Y., Fischer, Laura, Daams, Freek, and Mahawar, Kamal

Published
2022
Full Text
View/download PDF

3. Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis

Author

Bootsma, Boukje T., Plat, Victor D., van de Brug, Tim, Huisman, Daitlin E., Botti, M., van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Dejong, Cornelis H.C., Groot-Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., de Meijer, Vincent E., Luyer, Misha D., Nieuwenhuijs, Vincent B., Pranger, Bobby K., van Santvoort, Hjalmar C., Wijsman, Jan H., Zonderhuis, Barbara M., Kazemier, Geert, Besselink, Marc G., and Daams, Freek

Published
2022
Full Text
View/download PDF

4. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., van Berge Henegouwen, Mark I., Baas, Peter C., Bahadoer, Renu R., Belt, Eric J. T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J., van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P. R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E. N., Pierik, E. G. J. M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A. M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B. A. C., Stoop, Fanny J., Voeten, Daan M., Vugts, Guusje, Vijgen, Guy H. E. J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G. H., and Gisbertz, Suzanne S.

Published
2023
Full Text
View/download PDF

8. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

Author

Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., van Berge Henegouwen, Mark I., Henckens, Sofie P.G., Liu, Dajia, Gisbertz, Suzanne S., Kalff, Marianne C., Anderegg, Maarten C.J., Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., van Duijvendijk, Peter, Eshuis, Wietse J., Groenendijk, Richard P.R., Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D.P., Olthof, Pim B., Pierie, Jean Pierre E.N., Plat, Victor D., Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Sosef, Meindert N., Voeten, Daan M., Vijgen, Guy H.E.J., Bijlsma, Maarten F., Meijer, Sybren L., Hulshof, Maarten C.C.M., Oyarce, Cesar, Lagarde, Sjoerd M., van Laarhoven, Hanneke W.M., and van Berge Henegouwen, Mark I.

Abstract

BACKGROUND: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. METHODS: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. RESULTS: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). CONCLUSION: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.

Published
2024

9. Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., Henckens, Sofie P.G., Voeten, Daan M., Heineman, David J., Hulshof, Maarten C.C.M., van Laarhoven, Hanneke W.M., Eshuis, Wietse J., Baas, Peter C., Bahadoer, Renu R., Belt, Eric J.T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P.R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan W., Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E.N., Pierik, E.G.J.M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A.M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B.A.C., Stoop, Fanny J., Vugts, Guusje, Vijgen, Guy H.E.J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G.H., van Berge Henegouwen, Mark I., and Gisbertz, Suzanne S.

Published
2022
Full Text
View/download PDF

11. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., Henegouwen, Mark I. van Berge, Baas, Peter C., Bahadoer, Renu R., Belt, Eric J. T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J., van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P. R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E. N., Pierik, E. G. J. M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A. M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B. A. C., Stoop, Fanny J., Voeten, Daan M., Vugts, Guusje, Vijgen, Guy H. E. J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G. H., and Gisbertz, Suzanne S.

Published
2021
Full Text
View/download PDF

15. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.

Author

Henckens, Sofie P G, Liu, Dajia, Gisbertz, Suzanne S, Kalff, Marianne C, Anderegg, Maarten C J, Crull, David, Daams, Freek, van Dalsen, Annette D, Dekker, Jan Willem T, van Det, Marc J, van Duijvendijk, Peter, Eshuis, Wietse J, Groenendijk, Richard P R, Haveman, Jan Willem, van Hillegersberg, Richard, Luyer, Misha D P, Olthof, Pim B, Pierie, Jean-Pierre E N, Plat, Victor D, and Rosman, Camiel

Subjects
PROGNOSIS, COMBINED modality therapy, OVERALL survival, NEOADJUVANT chemotherapy, ADENOCARCINOMA, RECTAL cancer, HEARTBURN
Abstract

Background: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. Methods: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. Results: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). Conclusion: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site. In this Dutch nationwide cohort study, improved tumour response to neoadjuvant therapy was associated with a lower recurrence rate and higher overall survival rate. Among patients with recurrent disease, tumour regression grade (TRG) 1 was associated with a higher incidence of brain recurrences than TRG greater than 1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

MS CGO, Cancer, Externen Med. Onco, Kalff, Marianne C, Henegouwen, Mark I van Berge, Baas, Peter C, Bahadoer, Renu R, Belt, Eric J T, Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D, Dekker, Jan Willem T, van Det, Marc J, Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J, van Esser, Stijn, Gaspersz, Marcia P, Görgec, Burak, Groenendijk, Richard P R, Hartgrink, Henk H, van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B Feike, Koemans, Willem J, Kouwenhoven, Ewout A, Lagarde, Sjoerd M, Lecot, Frederik, van der Linden, Philip P, Luyer, Misha D P, Nieuwenhuijzen, Grard A P, Olthof, Pim B, van der Peet, Donald L, Pierie, Jean-Pierre E N, Pierik, E G J M Robert, Plat, Victor D, Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P, van Sandick, Johanna W, Scheer, Rene, Slootmans, Cettela A M, Sosef, Meindert N, Sosef, Odin V, de Steur, Wobbe O, Stockmann, Hein B A C, Stoop, Fanny J, Voeten, Daan M, Vugts, Guusje, Vijgen, Guy H E J, Weeda, Víola B, Wiezer, Marinus J, van Oijen, Martijn G H, Gisbertz, Suzanne S, MS CGO, Cancer, Externen Med. Onco, Kalff, Marianne C, Henegouwen, Mark I van Berge, Baas, Peter C, Bahadoer, Renu R, Belt, Eric J T, Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D, Dekker, Jan Willem T, van Det, Marc J, Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J, van Esser, Stijn, Gaspersz, Marcia P, Görgec, Burak, Groenendijk, Richard P R, Hartgrink, Henk H, van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B Feike, Koemans, Willem J, Kouwenhoven, Ewout A, Lagarde, Sjoerd M, Lecot, Frederik, van der Linden, Philip P, Luyer, Misha D P, Nieuwenhuijzen, Grard A P, Olthof, Pim B, van der Peet, Donald L, Pierie, Jean-Pierre E N, Pierik, E G J M Robert, Plat, Victor D, Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P, van Sandick, Johanna W, Scheer, Rene, Slootmans, Cettela A M, Sosef, Meindert N, Sosef, Odin V, de Steur, Wobbe O, Stockmann, Hein B A C, Stoop, Fanny J, Voeten, Daan M, Vugts, Guusje, Vijgen, Guy H E J, Weeda, Víola B, Wiezer, Marinus J, van Oijen, Martijn G H, and Gisbertz, Suzanne S

Published
2023

18. Short-term outcome for high-risk patients after esophagectomy

Author

Plat, Victor D, Stam, Wessel T, Bootsma, Boukje T, Straatman, Jennifer, Klausch, Thomas, Heineman, David J, van der Peet, Donald L, Daams, Freek, Plastic, Reconstructive and Hand Surgery, Surgery, Epidemiology and Data Science, APH - Methodology, Cardio-thoracic surgery, Cancer Center Amsterdam, CCA - Cancer Treatment and quality of life, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

Transthoracic esophagectomy (TTE) for esophageal cancer facilitates mediastinal dissection; however, it has a significant impact on cardiopulmonary status. High-risk patients may therefore be better candidates for transhiatal esophagectomy (THE) in order to prevent serious complications. This study addressed short-term outcome following TTE and THE in patients that are considered to have a higher risk of surgery-related morbidity. This population-based study included patients who underwent a curative esophagectomy between 2011 and 2018, registered in the Dutch Upper GI Cancer Audit. The Charlson comorbidity index was used to assign patients to a low-risk (score ≤ 1) and high-risk group (score ≥ 2). Propensity score matching was applied to produce comparable groups between high-risk patients receiving TTE and THE. Primary endpoint was mortality (in-hospital/30-day mortality), secondary endpoints included morbidity and oncological outcomes. Additionally, a matched subgroup analysis was performed, including only cervical reconstructions. Of 5,438 patients, 945 and 431 high-risk patients underwent TTE and THE, respectively. After propensity score matching, mortality (6.3 vs 3.3%, P = 0.050), overall morbidity, Clavien-Dindo ≥ 3 complications, pulmonary complications, cardiac complications and re-interventions were significantly more observed after TTE compared to THE. A significantly higher mortality after TTE with a cervical reconstruction was found compared to THE (7.0 vs. 2.2%, P = 0.020). Patients with a high Charlson comorbidity index predispose for a complicated postoperative course after esophagectomy, this was more outspoken after TTE compared to THE. In daily practice, these outcomes should be balanced with the lower lymph node yield, but comparable positive node count and radicality after THE.

Published
2022
Full Text
View/download PDF

19. Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy:A nationwide analysis

Author

Bootsma, Boukje T., Plat, Victor D., van de Brug, Tim, Huisman, Daitlin E., Botti, M., van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Dejong, Cornelis H.C., Groot-Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., de Meijer, Vincent E., Luyer, Misha D., Nieuwenhuijs, Vincent B., Pranger, Bobby K., van Santvoort, Hjalmar C., Wijsman, Jan H., Zonderhuis, Barbara M., Kazemier, Geert, Besselink, Marc G., Daams, Freek, Bootsma, Boukje T., Plat, Victor D., van de Brug, Tim, Huisman, Daitlin E., Botti, M., van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Dejong, Cornelis H.C., Groot-Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., de Meijer, Vincent E., Luyer, Misha D., Nieuwenhuijs, Vincent B., Pranger, Bobby K., van Santvoort, Hjalmar C., Wijsman, Jan H., Zonderhuis, Barbara M., Kazemier, Geert, Besselink, Marc G., and Daams, Freek

Abstract

Background: Somatostatin analogues (SA) are currently used to prevent postoperative pancreatic fistula (POPF) development. However, its use is controversial. This study investigated the effect of different SA protocols on the incidence of POPF after pancreatoduodenectomy in a nationwide population. Methods: All patients undergoing elective open pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2014–2017). Patients were divided into six groups: no SA, octreotide, lanreotide, pasireotide, octreotide only in high-risk (HR) patients and lanreotide only in HR patients. Primary endpoint was POPF grade B/C. The updated alternative Fistula Risk Score was used to compare POPF rates across various risk scenarios. Results: 1992 patients were included. Overall POPF rate was 13.1%. Lanreotide (10.0%), octreotide-HR (9.4%) and no protocol (12.7%) POPF rates were lower compared to the other protocols (varying from 15.1 to 19.1%, p = 0.001) in crude analysis. Sub-analysis in patients with HR of POPF showed a significantly lower rate of POPF when treated with lanreotide (10.0%) compared to no protocol, octreotide and pasireotide protocol (21.6–26.9%, p = 0.006). Octreotide-HR and lanreotide-HR protocol POPF rates were comparable to lanreotide protocol, however not significantly different from the other protocols. Multivariable regression analysis demonstrated lanreotide protocol to be positively associated with a low odds-ratio (OR) for POPF (OR 0.387, 95% CI 0.180–0.834, p = 0.015). In-hospital mortality rates were not affected. Conclusion: Use of lanreotide in all patients undergoing pancreatoduodenectomy has a potential protective effect on POPF development. Protocols for HR patients only might be favorable too. However, future studies are warranted to confirm these findings.

Published
2022

20. Recurrent Disease after Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study

Author

MS CGO, Cancer, Heelkunde Opleiding, Externen Med. Onco, Kalff, Marianne C, Henckens, Sofie P G, Voeten, Daan M, Heineman, David J, Hulshof, Maarten C C M, van Laarhoven, Hanneke W M, Eshuis, Wietse J, Baas, Peter C, Bahadoer, Renu R, Belt, Eric J T, Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D, Dekker, Jan Willem T, van Det, Marc J, Drost, Manon, Duijvendijk, Peter van, Esser, Stijn van, Gaspersz, Marcia P, Görgec, Burak, Groenendijk, Richard P R, Hartgrink, Henk H, Harst, Erwin van der, Haveman, Jan Willem, Heisterkamp, Joos, Hillegersberg, Richard van, Kelder, Wendy, Kingma, B Feike, Koemans, Willem J, Kouwenhoven, Ewout A, Lagarde, Sjoerd M, Lecot, Frederik, van der Linden, Philip P, Luyer, Misha D P, Nieuwenhuijzen, Grard A P, Olthof, Pim B, van der Peet, Donald L, Pierie, Jean-Pierre En, Pierik, E G J M Robert, Plat, Victor D, Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P, van Sandick, Johanna W, Scheer, Rene, Slootmans, Cettela AM, Sosef, Meindert N, Sosef, Odin V, de Steur, Wobbe O, Stockmann, Hein B A C, Stoop, Fanny J, Vugts, Guusje, Vijgen, Guy H E J, Weeda, Víola B, Wiezer, Marinus J, van Oijen, Martijn G H, van Berge Henegouwen, Mark I, Gisbertz, Suzanne S, MS CGO, Cancer, Heelkunde Opleiding, Externen Med. Onco, Kalff, Marianne C, Henckens, Sofie P G, Voeten, Daan M, Heineman, David J, Hulshof, Maarten C C M, van Laarhoven, Hanneke W M, Eshuis, Wietse J, Baas, Peter C, Bahadoer, Renu R, Belt, Eric J T, Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D, Dekker, Jan Willem T, van Det, Marc J, Drost, Manon, Duijvendijk, Peter van, Esser, Stijn van, Gaspersz, Marcia P, Görgec, Burak, Groenendijk, Richard P R, Hartgrink, Henk H, Harst, Erwin van der, Haveman, Jan Willem, Heisterkamp, Joos, Hillegersberg, Richard van, Kelder, Wendy, Kingma, B Feike, Koemans, Willem J, Kouwenhoven, Ewout A, Lagarde, Sjoerd M, Lecot, Frederik, van der Linden, Philip P, Luyer, Misha D P, Nieuwenhuijzen, Grard A P, Olthof, Pim B, van der Peet, Donald L, Pierie, Jean-Pierre En, Pierik, E G J M Robert, Plat, Victor D, Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P, van Sandick, Johanna W, Scheer, Rene, Slootmans, Cettela AM, Sosef, Meindert N, Sosef, Odin V, de Steur, Wobbe O, Stockmann, Hein B A C, Stoop, Fanny J, Vugts, Guusje, Vijgen, Guy H E J, Weeda, Víola B, Wiezer, Marinus J, van Oijen, Martijn G H, van Berge Henegouwen, Mark I, and Gisbertz, Suzanne S

Published
2022

22. Esophageal and gastric malignancies after bariatric surgery: a retrospective global study

Author

Parmar, Chetan, primary, Zakeri, Roxanna, additional, Abouelazayem, Mohamed, additional, Shin, Thomas H., additional, Aminian, Ali, additional, Mahmoud, Tala, additional, Abu Dayyeh, Barham K., additional, Wee, Melissa Y., additional, Fischer, Laura, additional, Daams, Freek, additional, Mahawar, Kamal, additional, Gallardo, Carlos Sosa, additional, Agustin, Cataldo, additional, Wright, Fernando, additional, Fuente, Ignacio, additional, Carbajo, Miguel, additional, Cal, Patricio, additional, Chisholm, Jacob, additional, Kow, Lilian, additional, Tan, Michael H.L., additional, Gan, Philip, additional, Gananadha, Sivakumar, additional, Felsenreich, Daniel M., additional, Prager, Gerhard, additional, Matthys, Chris, additional, Himpens, Jacques M., additional, Focquet, Marc A.M.R.M., additional, Ramos, Almino, additional, Nato, Manoel Galvano, additional, Vidal, Thiago, additional, Andalib, Amin, additional, Siblini, Aya, additional, Ferri, Lorenzo, additional, Abdarabo, Lina, additional, Nevo, Yehonatan, additional, Pescarus, Radu, additional, Yang, Wah, additional, Hamed, Hosam, additional, Liagre, Arnaud, additional, Bergeat, Damien, additional, Marie, De Montrichard, additional, Martini, Francesco, additional, Regis, François, additional, Genser, Laurent, additional, Skalli, Mehdi, additional, Nedelcu, Marius, additional, Smejkal, Milan, additional, Kassir, Radwan, additional, Nicolas, Regenet, additional, Stier, Christine, additional, Nedelcut, Dan-Sebastian, additional, Christodoulidis, Grigorios, additional, Vennapusa, Amar, additional, Kermansaravi, Mohammad, additional, Raziel, Asnat, additional, Sakran, Nasser, additional, Oldani, Alberto, additional, Boru, Cristian Eugeniu, additional, Mécheri, Fouzia, additional, Ciccarese, Francesca, additional, Cesana, Giovanni Carlo, additional, Musella, Mario, additional, Uccelli, Matteo, additional, Foletto, Mirto, additional, Auricchio, Pasquale, additional, Olmi, Stefano, additional, Seki, Yosuke, additional, Kasteleijn, Anne, additional, Van 'T Hof, Gerhard, additional, Apers, Jan A., additional, Hart, Judith W.H., additional, Van De Sande, Justin S.L., additional, Takkenberg, Marijn, additional, Feskens, Pierre B.G.M., additional, Snoekx, Rob, additional, Plat, Victor D., additional, Sandvik, Jorunn, additional, Kalinowski, Piotr, additional, Nabais, Celso, additional, Al-Bahrani, Ahmed Z., additional, Al Zoubi, Mohammad, additional, Bettonica, Carla, additional, Osorio, Javier, additional, Tejedor-Tejada, Javier, additional, Sanz, Lourdes M., additional, Cuadrado, Marta, additional, Moorjani, Rajesh Gianchandani, additional, Yannick, Fringeli, additional, Suter, Michel, additional, Borbély, Yves, additional, Joerg, Zehetner, additional, Barajas-Gamboa, Juan S., additional, Kroh, Matthew, additional, Kisiel, Aaron P., additional, Kamocka, Anna, additional, Immanuel, Arul, additional, Sgromo, Bruno, additional, Gopinath, Bussa, additional, Khoo, David, additional, Mukherjee, Samrat, additional, Pournaras, Dimitrios, additional, Underwood, Tim, additional, Griffiths, Ewen A., additional, Miller, Glenn V., additional, Jaretzke, Helen, additional, Dmitrewski, Jan, additional, Wadley, Martin S., additional, Al-Housni, Ragad, additional, Gillies, Richard S., additional, Singhal, Rishi, additional, Preston, Shaun R., additional, Robinson, Steven John, additional, Hawkins, William J., additional, Adamo, Marco, additional, El Kalaawy, Mohamed, additional, Gossage, James, additional, Crawford, Christopher B., additional, and Jaruvongvanich, Veeravich, additional

Published
2022
Full Text
View/download PDF

23. Short-term outcome for high-risk patients after esophagectomy.

Author

Plat, Victor D, Stam, Wessel T, Bootsma, Boukje T, Straatman, Jennifer, Klausch, Thomas, Heineman, David J, Peet, Donald L van der, Daams, Freek, and Group, Dutch Upper GI Cancer Audit

Subjects
*ESOPHAGECTOMY, *PROPENSITY score matching, *ESOPHAGEAL cancer, *TREATMENT effectiveness
Abstract

Transthoracic esophagectomy (TTE) for esophageal cancer facilitates mediastinal dissection; however, it has a significant impact on cardiopulmonary status. High-risk patients may therefore be better candidates for transhiatal esophagectomy (THE) in order to prevent serious complications. This study addressed short-term outcome following TTE and THE in patients that are considered to have a higher risk of surgery-related morbidity. This population-based study included patients who underwent a curative esophagectomy between 2011 and 2018, registered in the Dutch Upper GI Cancer Audit. The Charlson comorbidity index was used to assign patients to a low-risk (score ≤ 1) and high-risk group (score ≥ 2). Propensity score matching was applied to produce comparable groups between high-risk patients receiving TTE and THE. Primary endpoint was mortality (in-hospital/30-day mortality), secondary endpoints included morbidity and oncological outcomes. Additionally, a matched subgroup analysis was performed, including only cervical reconstructions. Of 5,438 patients, 945 and 431 high-risk patients underwent TTE and THE, respectively. After propensity score matching, mortality (6.3 vs 3.3%, P  = 0.050), overall morbidity, Clavien-Dindo ≥ 3 complications, pulmonary complications, cardiac complications and re-interventions were significantly more observed after TTE compared to THE. A significantly higher mortality after TTE with a cervical reconstruction was found compared to THE (7.0 vs. 2.2%, P  = 0.020). Patients with a high Charlson comorbidity index predispose for a complicated postoperative course after esophagectomy, this was more outspoken after TTE compared to THE. In daily practice, these outcomes should be balanced with the lower lymph node yield, but comparable positive node count and radicality after THE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review.

Author

Plat, Victor D, Rossen, Tessel M van, Daams, Freek, Boer, Nanne K de, Meij, Tim G J de, Budding, Andries E, Vandenbroucke-Grauls, Christina M J E, and Peet, Donald L van der

Subjects
*ESOPHAGEAL cancer, *CANCER prognosis, *CANCER treatment, *ADJUVANT chemotherapy, *FECAL microbiota transplantation, *BIBLIOGRAPHIC databases
Abstract

Background: The role of esophageal microbiota in esophageal cancer treatment is gaining renewed interest, largely driven by novel DNA-based microbiota analysis techniques. The aim of this systematic review is to provide an overview of current literature on the possible association between esophageal microbiota and outcome of esophageal cancer treatment, including tumor response to (neo)adjuvant chemo(radio)therapy, short-term surgery-related complications, and long-term oncological outcome. Methods: A systematic review of literature was performed, bibliographic databases were searched and relevant articles were selected by two independent researchers. The Newcastle-Ottawa scale was used to estimate the quality of included studies. Results: The search yielded 1303 articles, after selection and cross-referencing, five articles were included for qualitative synthesis and four studies were considered of good quality. Two articles addressed tumor response to neoadjuvant chemotherapy and described a correlation between high intratumoral Fusobacterium nucleatum levels and a poor response. One study assessed surgery-related complications, in which no direct association between esophageal microbiota and occurrence of complications was observed. Three studies described a correlation between shortened survival and high levels of intratumoral F. nucleatum , a low abundance of Proteobacteria and high abundances of Prevotella and Streptococcus species. Conclusions: Current evidence points towards an association between esophageal microbiota and outcome of esophageal cancer treatment and justifies further research. Whether screening of the individual esophageal microbiota can be used to identify and select patients with a predisposition for adverse outcome needs to be further investigated. This could lead to the development of microbiota-based interventions to optimize esophageal microbiota composition, thereby improving outcome of patients with esophageal cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Non-Invasive Detection of Anastomotic Leakage Following Esophageal and Pancreatic Surgery by Urinary Analysis.

Author

Plat, Victor D., van Gaal, Nora, Covington, James A., Neal, Matthew, de Meij, Tim G. J., van der Peet, Donald L., Zonderhuis, Babs, Kazemier, Geert, de Boer, Nanne K. H., and Daams, Freek

Abstract

Background: Esophagectomy or pancreaticoduodenectomy is the standard surgical approach for patients with tumors of the esophagus or pancreatic head. Postoperative mortality is strongly correlated with the occurrence of anastomotic leakage (AL). Delay in diagnosis leads to delay in treatment, which ratifies the need for development of novel and accurate non-invasive diagnostic tests for detection of AL. Urinary volatile organic compounds (VOCs) reflect the metabolic status of an individual, which is associated with a systemic immunological response. The aim of this study was to determine the diagnostic accuracy of urinary VOCs to detect AL after esophagectomy or pancreaticoduodenectomy. Methods: In the present study, urinary VOCs of 63 patients after esophagectomy (n = 31) or pancreaticoduodenectomy (n = 32) were analyzed by means of field asymmetric ion mobility spectrometry. AL was defined according to international study groups. Results: AL was observed in 15 patients (24%). Urinary VOCs of patients with AL after pancreaticoduodenectomy could be distinguished from uncomplicated controls, area under the curve 0.85 (95% CI 0.76–0.93), sensitivity 76%, and specificity 77%. However, this was not observed following esophagectomy, area under the curve 0.51 (95% CI 0.37–0.65). Conclusion: In our study population AL following pancreaticoduodenectomy could be discriminated from uncomplicated controls by means of urinary VOC analysis, NTC03203434. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results